Cognito’s Alzheimer’s Therapy Shows Promising Results in Mild Patients Despite Missing Primary Trial Goal

0
15
Spectris

CAMBRIDGE, Mass.–Cognito has reported encouraging results for its experimental Alzheimer’s disease therapy, Spectris, among patients with mild symptoms, although the treatment failed to meet its primary endpoint in a pivotal clinical trial involving patients with mild-to-moderate disease.

The Cambridge-based company announced findings from its 12-month HOPE study, which evaluated Spectris, a noninvasive therapy that delivers 40 Hz light and sound stimulation during daily at-home sessions.

The randomized, double-blind, sham-controlled trial enrolled 673 participants with mild-to-moderate Alzheimer’s disease. While the treatment did not demonstrate a statistically significant benefit in the overall study population, a prespecified subgroup of 395 patients with mild Alzheimer’s showed favorable results across five measures of cognitive ability and daily functioning.

Among patients with mild disease, Spectris was associated with a 56% slowing of decline in daily functioning, measured by the Alzheimer’s Disease Cooperative Study–Activities of Daily Living scale, compared with sham treatment after 12 months.

The therapy also demonstrated a 47% slowing of decline on the Clinical Dementia Rating–Sum of Boxes scale, which measures cognition and function.

Both findings showed nominal statistical significance, although the reported p-values were not adjusted for multiple comparisons.

Additional measures showed a 53% slowing of decline in instrumental activities of daily living, a 42% slowing on a combined measure of cognition and daily function, and a 29% slowing on a cognitive assessment.

However, the latter two measures did not reach nominal statistical significance.

Cognito estimated that the observed differences corresponded to approximately 5.3 months of delayed decline in daily functioning and 5.6 months in cognition and function over the study period. The company cautioned that these estimates are exploratory.

“HOPE was designed around a simple but important question: Can we help people living with Alzheimer’s disease preserve more of what matters most in their everyday lives?” said Christian Howell, Chief Executive Officer of Cognito.

“Based on our feasibility data, we felt a responsibility to study Spectris in as broad a population as possible. We had hoped to see an effect across that overall population, and we did not. Importantly, what we saw in participants in the mild subgroup brings real hope to patients and families who urgently need alternative treatments. Our priority now is to work with the FDA toward authorization of Spectris AD™ and bring this potential new therapeutic approach to the people and families who need it.”

The study included participants with baseline Mini-Mental State Examination scores ranging from 15 to 28, with biomarker confirmation of Alzheimer’s disease.

Researchers divided participants into mild and moderate disease subgroups to evaluate whether treatment responses differed according to disease severity.

In the overall primary analysis population of 663 participants, Spectris failed to demonstrate a statistically significant improvement over sham treatment on the study’s primary composite measure of cognition and daily function. Secondary endpoints in the overall population also showed no statistically significant differences.

A separate prespecified analysis involving 169 participants with mild Alzheimer’s who met treatment-use requirements showed larger differences between the treatment and sham groups.

Among these participants, Spectris was associated with an 82% slowing of decline in daily function, a 64% slowing on the Clinical Dementia Rating–Sum of Boxes scale, and a 73% slowing on the combined cognition and daily-function measure.

Participants included in this analysis had completed at least six months of treatment, maintained at least 70% compliance with device use, and had no major protocol deviations.

Cognito cautioned that these findings do not establish a causal relationship between treatment adherence and improved clinical outcomes.

“For people living with Alzheimer’s disease and their families, what is most meaningful is the ability to keep doing everyday things, so it’s notable that the strongest effects in the mild subgroup were on measures of daily function,” said Allan Levey, M.D., Ph.D., Director of the Emory Alzheimer’s Disease Research Center at Emory University School of Medicine.

“The consistency across clinical and functional measures is encouraging. The difference between earlier and more advanced disease, which is a well-known and almost expected difference that is seen with the approved disease-modifying treatments, also reinforces the importance of understanding when interventions may have the greatest opportunity to preserve cognition and function.”

Cognito also evaluated the findings using the What Matters Most framework, developed through the Alzheimer’s Disease Patient and Caregiver Engagement initiative led by UsAgainstAlzheimer’s.

The framework assesses aspects of everyday life that patients and caregivers consider particularly important, including independence, communication, thought processing, daily activities, emotional well-being, and social engagement.

In an exploratory analysis involving 367 patients with mild Alzheimer’s, Spectris was associated with a 60% slowing of decline on the framework’s overall composite score compared with sham treatment.

The analysis also found a 79% slowing of decline in thought processing and a 60% slowing in daily activities.

Among patients who met the study’s treatment-use requirements, the estimated slowing of decline on the overall composite measure reached 86%.

“Early diagnosis and treatment are critical in the fight against Alzheimer’s disease,” said Ali Rezai, M.D., Executive Chair of the WVU Rockefeller Neuroscience Institute.

“Cognito’s Spectris is a non-invasive, home-based therapy with a favorable safety profile. This novel, nonpharmacological approach has the potential to expand the toolbox for neurologists treating patients with mild Alzheimer’s disease. Importantly, by evaluating outcomes through the What Matters Most framework, Cognito is helping connect clinical findings to the everyday abilities that patients and their families care about most.”

The company reported that Spectris was generally well tolerated, with no unanticipated adverse device effects observed in either treatment group.

Adverse device effects were reported in 18.3% of participants receiving Spectris and 15.5% of those receiving sham treatment.

The most frequently reported effects included headaches, tinnitus, fatigue, dizziness, hallucinations, seizures, and ear pain.

Headaches occurred in 5.7% of patients receiving Spectris, compared with 3.9% in the sham group. Tinnitus was reported in 3.3% and 1.2% of patients, respectively.

Cognito is now preparing to engage with the U.S. Food and Drug Administration to discuss a potential regulatory pathway for Spectris AD in patients with early symptomatic Alzheimer’s disease.

The investigational therapy has received FDA Breakthrough Device designation, and the company plans to discuss the clinical evidence and requirements for a potential De Novo authorization submission.

Cognito also intends to continue monitoring patients through the HOPE open-label extension program to evaluate longer-term treatment outcomes.

The findings were scheduled for presentation November 16 at the 19th Clinical Trials on Alzheimer’s Disease Conference.

Spectris remains investigational, and its effectiveness has not been established for regulatory authorization.

Leave A Reply

Please enter your comment!
Please enter your name here